Minerva Medica 2021 June;112(3):315-7

DOI: 10.23736/S0026-4806.21.07450-4

language: English

Neuroendocrine neoplasms: what we have learned and what the future holds in the pharmacological treatment

Giovanni VITALE ^{1, 2} ✉, Luigi BARREA ^{3, 4}, Antonio AVERSA ⁵

¹ IRCCS Istituto Auxologico Italiano, Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Cusano Milanino, Milan, Italy; ² Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy; ³ Unit of Endocrinology, Department of Clinical Medicine and Surgery, Medical School of Naples, Federico II University, Naples, Italy; ⁴ Unit of Endocrinology, Department of Clinical Medicine and Surgery, Centro Italiano per la Cura e il Benessere del Paziente con Obesità (C.I.B.O), Medical School of Naples, Federico II University, Naples, Italy; ⁵ Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy

HTML PDF

top of page

YOUR ACCOUNT

YOUR ORDERS

SHOPPING BASKET

HOW TO ORDER

YOUR SUBSCRIPTIONS

YOUR ARTICLES

YOUR EBOOKS

COUPON

ACCESSIBILITY

Minerva Medica 2021 June;112(3):315-7

Neuroendocrine neoplasms: what we have learned and what the future holds in the pharmacological treatment

Publication History

Cite this article as

Corresponding author e-mail

Share